Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd (RDY) is an India‑based multinational pharmaceutical company with a market cap of about $12.19bn. It develops, manufactures and sells generics, active pharmaceutical ingredients (APIs), over‑the‑counter products and a growing biosimilars pipeline across the US, Europe, India and emerging markets. Investors should note its mix of stable revenue from established generics and potential upside from specialty products and R&D, alongside common sector headwinds such as pricing pressure, regulatory approvals, patent litigation and currency exposure. Financial performance can be cyclical and influenced by product approvals, competitive launches and government pricing policies. This summary provides general, educational information only and is not personalised investment advice; suitability depends on an investor’s objectives, time horizon and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Dr. Reddy's stock, indicating limited growth potential at the moment.
Financial Health
Dr. Reddy's Laboratories is performing well with strong revenue and profits, indicating healthy operations.
Dividend
Dr. Reddy's Laboratories offers a below-average dividend yield of 0.62%. If you invested $1000, you would be paid $6.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RDY
Walgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketNavigating U.S.-India Trade Tensions
The United States has imposed tariffs of up to 50% on Indian exports, creating a potential advantage for international competitors. This theme focuses on companies that may capture market share from affected Indian industries and Indian firms in exempted sectors.
Published: August 28, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketNext-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketIndia's Credit Growth Story
India's banking sector is showing impressive stability with balanced 10% growth in both loans and deposits. These carefully selected stocks and ETFs represent companies positioned to thrive as increased credit availability fuels corporate spending and economic momentum across the country.
Published: June 30, 2025
Explore BasketIndia's Economic Fortress
India's impressive $698 billion foreign exchange reserves create a shield against global economic uncertainty. Our analysts have carefully selected companies set to thrive from a stable rupee, reduced import costs, and increased foreign investment confidence.
Published: June 30, 2025
Explore BasketMade in India
Say namaste to a collection of promising Indian companies carefully selected by our professional analysts. These stocks represent opportunities in the world's most populous nation as it grows toward becoming the third-largest global economy.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Generics and R&D
A broad generics franchise plus R&D into biosimilars can support revenue growth, though pricing pressure and competition may weigh on margins.
Global Footprint
Sales across the US, Europe, India and emerging markets diversify exposure but bring regulatory and currency risks investors should monitor.
Regulatory & Patent Risks
Approvals, patent disputes and pricing policies can cause share‑price volatility — follow pipeline updates and litigation developments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
